FOUR-YEAR FOLLOW-UP OF MYCOPHENOLATE MOFETIL FOR GRAFT RESCUE IN LIVER ALLOGRAFT RECIPIENTS1

Abstract

MMF seems to be an effective alternative immunosuppressive in patients failing CsA-based conventional therapy. MMF may be of particular benefit in patients who do not tolerate CsA or tacrolimus. The long-term safety profile is similar to that of other immunosuppressives.